Allarity Therapeutics Announces Reverse Stock Split of Common Stock
Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24,...
Clinical Trial
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal terms included €20M upfront payment,...
AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development
Emmanuel Hanon, PhD, will chair the company’s scientific advisory board. Professor Peter Piot (MD, PhD) and Professor Patrick Soentjens (MD,...
Bioasis Provides Update on Business Operations
NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset...
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of...
Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary
NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the...
Aptose Reports Results for the Fourth Quarter and Full Year 2022
─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of...
AVITA Medical Appoints New Non-Executive Member to the Board of Directors
VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative...
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the interim analysis of...
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout...
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline...
Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer
Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approvalGARDEN CITY, N.Y.,...
PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
Orion and Bayer expand clinical development program for darolutamide in prostate cancer
ORION CORPORATION PRESS RELEASE 23 March 2023 at 15:00 EET Orion and Bayer expand clinical development program for darolutamide in prostate...
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Gerry O’Sullivan, the Latest Member to Join Microbot Medical’s Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY® Robotic System Through Regulatory, Clinical and Commercialization Phases
Widely Published Interventional Radiologist Has Earned Well-Regarded Reputation Working with Prestigious Medical Centers in the U.S. and Europe The addition...
IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that NXC-201 treatment...